A phase I study involving children with r/r B-ALL and the humanized anti-CD19 mAb loncastuximab tesirine (or ADCT-402) was terminated early because of slow accrual (NCT02669264). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.